Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Pierre Fumoleau
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Procedures
Chemicals & Drugs
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
26
Fargeot, Pierre
20
Kerbrat, Pierre
18
Campone, Mario
15
Bonneterre, Jacques
15
Wanders, Jantien
14
Roché, Henri
14
Chollet, Philippe
12
Namer, Moïse
11
Chevallier, Bernard
11
Coudert, Bruno
10
Dittrich, Christian
9
Goudier, Marie-Josèphe
9
Monnier, Alain
8
Dieras, Véronique
8
Chatal, Jean-François
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Pierre Fumoleau (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Boidot Romain; Vegran Frédérique; Soubeyrand Marie-Sophie; Fumoleau Pierre; Coudert Bruno; Lizard-Nacol Sarab
Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Cancer investigation 2009;27(5):521-8.
-
2009: Arnould Laurent; Coudert Bruno; Fumoleau Pierre
Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2733; author reply 2734-5.
-
2009: Chan Stephen; Romieu Gilles; Huober Jens; Delozier Thierry; Tubiana-Hulin Michele; Schneeweiss Andreas; Lluch Ana; Llombart Antonio; du Bois Andreas; Kreienberg Rolf; Mayordomo Jose Ignacio; Antón Antonio; Harrison Mark; Jones Alison; Carrasco Eva; Vaury A Thareau; Frimodt-Moller Bente; Fumoleau Pierre
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1753-60.
-
2008: Raymond Eric; Brandes Alba A; Dittrich Christian; Fumoleau Pierre; Coudert Bruno; Clement Paul M J; Frenay Marc; Rampling Roy; Stupp Roger; Kros Johan M; Heinrich Michael C; Gorlia Thierry; Lacombe Denis; van den Bent Martin J;
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4659-65.
-
2008: Ladoire Sylvain; Arnould Laurent; Apetoh Lionel; Coudert Bruno; Martin Francois; Chauffert Bruno; Fumoleau Pierre; Ghiringhelli François
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2413-20.
-
2008: Favier Laure; Isambert Nicolas; Zanetta Sylvie; Ferrant Emmanuelle; Mayer Françoise; Chauffert Bruno; Fumoleau Pierre; Garnier Jérome; Biville Fabienne; Coudert Bruno
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
Breast (Edinburgh, Scotland) 2008;17(1):36-41.
-
2007: Berriolo-Riedinger Alina; Touzery Claude; Riedinger Jean-Marc; Toubeau Michel; Coudert Bruno; Arnould Laurent; Boichot Christophe; Cochet Alexandre; Fumoleau Pierre; Brunotte François
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
European journal of nuclear medicine and molecular imaging 2007;34(12):1915-24.
-
2007: Arnould Laurent; Arveux Patrick; Couturier Jerome; Gelly-Marty Marion; Loustalot Catherine; Ettore Francette; Sagan Christine; Antoine Martine; Penault-Llorca Frederique; Vasseur Berangere; Fumoleau Pierre; Coudert Bruno P
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6404-9.
-
2007: Thomas Eva; Tabernero Josep; Fornier Monica; Conté Pierfranco; Fumoleau Pierre; Lluch Ana; Vahdat Linda T; Bunnell Craig A; Burris Howard A; Viens Patrice; Baselga José; Rivera Edgardo; Guarneri Valentina; Poulart Valerie; Klimovsky Judith; Lebwohl David; Martin Miguel
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3399-406.
-
2007: Fumoleau P; Coudert B; Isambert N; Ferrant E
Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 5():v9-15.
-
2007: Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier M-J; Audhuy B; Simon H; Montcuquet P; Eymard J-C; Walter S; Clavère P; Guastalla J-P;
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
British journal of cancer 2007;96(11):1633-8.
-
2007: Campone M; Isambert N; Bourbouloux E; Maury S; Monin-Baroille P; Berille J; Fumoleau P
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
Cancer chemotherapy and pharmacology 2007;59(5):689-95.
-
2007: Fumoleau Pierre; Coudert Bruno; Mayer Françoise; Isambert Nicolas; Favier Laure; Ferrant Emmanuelle
[Angiogenesis targeting in breast cancer]
Bulletin du cancer 2007;94(7 Suppl):F199-206.
-
2007: Fumoleau Pierre; Campone Mario; Coudert Bruno; Mayer Françoise; Favier Laure; Ferrant Emanuelle
[Targeting ErbB receptors in breast cancer]
Bulletin du cancer 2007;94(7 Suppl):F147-70.
-
2006: Roché Henri; Fumoleau Pierre; Spielmann Marc; Canon Jean-Luc; Delozier Thierry; Serin Daniel; Symann Michel; Kerbrat Pierre; Soulié Patrick; Eichler Françoise; Viens Patrice; Monnier Alain; Vindevoghel Anita; Campone Mario; Goudier Marie-Josèphe; Bonneterre Jacques; Ferrero Jean-Marc; Martin Anne-Laure; Genève Jean; Asselain Bernard
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(36):5664-71.
-
2006: Veyret Corinne; Levy Christelle; Chollet Philippe; Merrouche Yacine; Roche Henri; Kerbrat Pierre; Fumoleau Pierre; Fargeot Pierre; Clavere Pierre; Chevallier Bernard
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Cancer 2006;107(11):2535-44.
-
2006: Molucon-Chabrot Cécile; Isambert Nicolas; Benoit Laurent; Zanetta Sylvie; Fraisse Jean; Guilland Jean-Claude; Royer Bernard; Monin-Baroille Pascale; Flesch Michel; Fargeot Pierre; Coudert Bruno; Mayer Françoise; Fumoleau Pierre; Chauffert Bruno
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Anti-cancer drugs 2006;17(10):1211-7.
-
2006: Campone M; Cortes-Funes H; Vorobiof D; Martin M; Slabber C F; Ciruelos E; Bourbouloux E; Mendiola C; Delgado F M; Colin C; Aslanis V; Fumoleau P
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
British journal of cancer 2006;95(9):1161-6.
-
2006: Grangeasse Ludwig; Coudert Bruno; Pivot Xavier; Fumoleau Pierre; Depierre Alain; Chauffert Bruno; Huichard Sylvette; Woronoff-Lemsi Marie-Christine; Arveux Patrick; Limat Samuel
[Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]
Bulletin du cancer 2006;93(10):1047-54.
-
2006: Héry Michel; Bonneterre Jacques; Roché Henri; Luporsi Elisabeth; Kerbrat Pierre; Namer Moïse; Fumoleau Pierre; Monnier Alain; Fargeot Pierre
Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial.
Bulletin du cancer 2006;93(10):E109-14.
-
2006: Campone Mario; Fumoleau Pierre; Viens Patrice; Diéras Véronique; Pujade-Lauraine Eric; Serin Daniel; Petit Thierry; Espié Marc; Kayitalire Louis; Bozec Laurence; Pouillart Pierre
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Breast (Edinburgh, Scotland) 2006;15(5):601-9.
-
2006: Zhang Steven; Zannikos Peter; Awada Ahmad; Piccart-Gebhart Martine; Dirix Luc Y; Fumoleau Pierre; Verhaeghe Tom; Francois Marc; De Porre Peter
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.
Journal of clinical pharmacology 2006;46(10):1116-27.
-
2006: Roché H; Kerbrat P; Bonneterre J; Fargeot P; Fumoleau P; Monnier A; Clavère P; Goudier M-J; Chollet P; Guastalla J-P; Serin D
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1221-7.
-
2006: Paoletti Xavier; Baron Benoît; Schöffski Patrick; Fumoleau Pierre; Lacombe Denis; Marreaud Sandrine; Sylvester Richard
Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study.
European journal of cancer (Oxford, England : 1990) 2006;42(10):1362-8.
-
2006: Johnson Peter; Geldart Thomas; Fumoleau Pierre; Pinel Marie-Claire; Nguyen Laurent; Judson Ian
Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks.
Investigational new drugs 2006;24(3):223-31.
-
2006: Fumoleau P; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier M-J; Luporsi E;
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):85-92.
-
2005: Adler Michael; Langer Martin; Witthohn Klaus; Wilhelm-Ogunbiyi Karin; Schöffski Patrick; Fumoleau Pierre; Niemeyer Christof M
Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samples.
Journal of pharmaceutical and biomedical analysis 2005;39(5):972-82.
-
2005: Diéras Véronique; Bonneterre Jacques; Laurence Valérie; Degardin Marian; Pierga Jean-Yves; Bonneterre Marie-Edith; Marreaud Sandrine; Lacombe Denis; Fumoleau Pierre
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6256-60.
-
2005: Campone Mario; Fumoleau Pierre; Bourbouloux Emmanuelle; Kerbrat Pierre; Roché Henri
Taxanes in adjuvant breast cancer setting: which standard in Europe?
Critical reviews in oncology/hematology 2005;55(3):167-75.
-
2005: Campone M; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier M-J; Fumoleau P
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1343-51.
-
2005: Farmer Pierre; Bonnefoi Herve; Becette Veronique; Tubiana-Hulin Michele; Fumoleau Pierre; Larsimont Denis; Macgrogan Gaetan; Bergh Jonas; Cameron David; Goldstein Darlene; Duss Stephan; Nicoulaz Anne-Laure; Brisken Cathrin; Fiche Maryse; Delorenzi Mauro; Iggo Richard
Identification of molecular apocrine breast tumours by microarray analysis.
Oncogene 2005;24(29):4660-71.
-
2005: Praga Claudio; Bergh Jonas; Bliss Judith; Bonneterre Jacques; Cesana Bruno; Coombes R Charles; Fargeot Pierre; Folin Annika; Fumoleau Pierre; Giuliani Rosa; Kerbrat Pierre; Hery Michel; Nilsson Jonas; Onida Francesco; Piccart Martine; Shepherd Lois; Therasse Patrick; Wils Jacques; Rogers David
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4179-91.
-
2005: van Kesteren Charlotte; Zandvliet Anthe S; Karlsson Mats O; Mathôt Ron A A; Punt Cornelis J A; Armand Jean-Pierre; Raymond Eric; Huitema Alwin D R; Dittrich Christian; Dumez Herlinde; Roché Henri H; Droz Jean-Pierre; Ravic Miroslav; Yule S Murray; Wanders Jantien; Beijnen Jos H; Fumoleau Pierre; Schellens Jan H M
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
Investigational new drugs 2005;23(3):225-34.
-
2005: Theodore C; Geoffrois L; Vermorken J B; Caponigro F; Fiedler W; Chollet P; Ravaud A; Peters G J; de Balincourt C; Lacombe D; Fumoleau P
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
European journal of cancer (Oxford, England : 1990) 2005;41(8):1150-7.
-
2005: Bonneterre Jacques; Roché Henri; Kerbrat Pierre; Brémond Alain; Fumoleau Pierre; Namer Moïse; Goudier Marie-Josèphe; Schraub Simon; Fargeot Pierre; Chapelle-Marcillac Isabelle
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2686-93.
-
2005: Ravaud Alain; Cerny Thomas; Terret Catherine; Wanders Jantien; Bui Binh Nguyen; Hess Dagmar; Droz Jean-Pierre; Fumoleau Pierre; Twelves Chris
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
European journal of cancer (Oxford, England : 1990) 2005;41(5):702-7.
-
2005: Smyth J F; Aamdal S; Awada A; Dittrich C; Caponigro F; Schöffski P; Gore M; Lesimple T; Djurasinovic N; Baron B; Ravic M; Fumoleau P; Punt C J A;
Phase II study of E7070 in patients with metastatic melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):158-61.
-
2004: Diéras Véronique; Fumoleau Pierre; Romieu Gilles; Tubiana-Hulin Michèle; Namer Moïse; Mauriac Louis; Guastalla Jean-Paul; Pujade-Lauraine Eric; Kerbrat Pierre; Maillart Philippe; Pénault-Llorca Frédérique; Buyse Marc; Pouillart Pierre
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(24):4958-65.
-
2004: Duffaud F; Borner M; Chollet P; Vermorken J B; Bloch J; Degardin M; Rolland F; Dittrich C; Baron B; Lacombe D; Fumoleau P;
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
European journal of cancer (Oxford, England : 1990) 2004;40(18):2748-52.
-
2004: Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1816-24.
-
2004: Campone Mario; Bourbouloux Emmanuelle; Fumoleau Pierre
[Cardiac dysfunction induced by trastuzumab]
Bulletin du cancer 2004;91 Suppl 3():166-73.
-
2004: Pierga J Y; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin F L; Goudier M J; Gil-Delgado M; Baticle J L; Namer M; Chollet P; Sutherland W; Barats J C;
Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Breast cancer research and treatment 2004;88(2):117-29.
-
2004: Fumoleau Pierre; Cameron David
Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer.
Seminars in oncology 2004;31(5 Suppl 10):45-50.
-
2004: Bonneterre Jacques; Roché Henri; Kerbrat Pierre; Fumoleau Pierre; Goudier Marie-Josèphe; Fargeot Pierre; Montcuquet Philippe; Clavère Pierre; Barats Jean-Claude; Monnier Alain; Veyret Corinne; Datchary Jean; Van Praagh Isabelle; Chapelle-Marcillac Isabelle
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3070-9.
-
2004: Misset J L; Gamelin E; Campone M; Delaloge S; Latz J E; Bozec L; Fumoleau P
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(7):1123-9.
-
2004: Peters Godefridus J; Noordhuis Paul; Van Groeningen Cornelis J; Giaccone Giuseppe; Holwerda Ulbe; Voorn Daphne; Schrijvers Ad; Schornagel Jan H; Beijnen Jos H; Fumoleau Pierre; Schellens Jan H M
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4072-6.
-
2004: Punt C J A; de Jonge M J A; Monfardini S; Daugaard G; Fiedler W; Baron B; Lacombe D; Fumoleau P;
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
European journal of cancer (Oxford, England : 1990) 2004;40(9):1332-4.
-
2004: Pegram Mark D; Pienkowski Tadeusz; Northfelt Donald W; Eiermann Wolfgang; Patel Ravi; Fumoleau Pierre; Quan Eleonor; Crown John; Toppmeyer Deborah; Smylie Michael; Riva Alessandro; Blitz Sandra; Press Michael F; Reese David; Lindsay Mary-Ann; Slamon Dennis J
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Journal of the National Cancer Institute 2004;96(10):759-69.
-
2004: Giaccone G; Smit E F; de Jonge M; Dansin E; Briasoulis E; Ardizzoni A; Douillard J-Y; Spaeth D; Lacombe D; Baron B; Bachmann P; Fumoleau P;
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
European journal of cancer (Oxford, England : 1990) 2004;40(5):667-72.
-
2004: Fumoleau P; Largillier R; Clippe C; Dièras V; Orfeuvre H; Lesimple T; Culine S; Audhuy B; Serin D; Curé H; Vuillemin E; Morère J-F; Montestruc F; Mouri Z; Namer M
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(4):536-42.
-
2004: Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Cancer chemotherapy and pharmacology 2004;53(3):233-8.
-
2004: Jézéquel P; Campion L; Joalland M-P; Millour M; Dravet F; Classe J-M; Delecroix V; Deporte R; Fumoleau P; Ricolleau G
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.
British journal of cancer 2004;90(1):189-93.
-
2004: Chau Ian; Legge Sally; Fumoleau Pierre
The vital role of education and information in patients receiving capecitabine (Xeloda).
European journal of oncology nursing : the official journal of European Oncology Nursing Society 2004;8 Suppl 1():S41-53.
-
2003: Dittrich Christian; Dumez Herlinde; Calvert Hilary; Hanauske Axel; Faber Marije; Wanders Jantien; Yule Murray; Ravic Miroslav; Fumoleau Pierre
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5195-204.
-
2003: Ganem G; Tubiana-Hulin M; Fumoleau P; Combe M; Misset J-L; Vannetzel J-M; Bachelot T; De Ybarlucea L R; Lotz V; Bendahmane B; Dieras V
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(11):1623-8.
-
2003: Briasoulis E; Pavlidis N; Terret C; Bauer J; Fiedler W; Schöffski P; Raoul J L; Hess D; Selvais R; Lacombe D; Bachmann P; Fumoleau P
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
European journal of cancer (Oxford, England : 1990) 2003;39(16):2334-40.
-
2003: Campone Mario; Kerbrat Pierre; Roché Henri; Bennouna Jaffar; Cuillière Jean-Claude; Le Mevel Bernard; Fumoleau Pierre
[Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer]
Bulletin du cancer 2003;90(10):851-64.
-
2003: Fumoleau Pierre; Blum Joanne L; Reichardt Peter
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
Cancer 2003;98(6):1325-6; author reply 1326-7.
-
2003: Comets Emmanuelle; Ikeda Kazumasa; Hoff Paulo; Fumoleau Pierre; Wanders Jantien; Tanigawara Yusuke
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Journal of pharmacokinetics and pharmacodynamics 2003;30(4):257-83.
-
2003: Dittrich Christian; Dieras Veronique; Kerbrat Pierre; Punt Cornelis; Sorio Roberto; Caponigro Francesco; Paoletti Xavier; de Balincourt Christine; Lacombe Denis; Fumoleau Pierre
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
Investigational new drugs 2003;21(3):347-52.
-
2003: Urien S; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Deporte-Fety R
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Cancer chemotherapy and pharmacology 2003;52(2):99-107.
-
2003: Campone Mario; Merlin Jean-Louis; Fumoleau Pierre
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]
Bulletin du cancer 2003;90(7):614-22.
-
2003: Peters G J; Noordhuis P; Van Kuilenburg A B P; Schornagel J H; Gall H; Turner S L; Swart M S; Voorn D; Van Gennip A H; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen C J
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Cancer chemotherapy and pharmacology 2003;52(1):1-12.
-
2003: Chollet P; Schöffski P; Weigang-Köhler K; Schellens J H M; Cure H; Pavlidis N; Grünwald V; De Boer R; Wanders J; Fumoleau P;
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
European journal of cancer (Oxford, England : 1990) 2003;39(9):1264-70.
-
2003: Fumoleau Pierre
Gemcitabine combined with docetaxel in metastatic breast cancer.
Seminars in oncology 2003;30(2 Suppl 3):15-8.
-
2003: Van den Brande J; Schöffski P; Schellens J H M; Roth A D; Duffaud F; Weigang-Köhler K; Reinke F; Wanders J; de Boer R F; Vermorken J B; Fumoleau P
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
British journal of cancer 2003;88(5):648-53.
-
2003: Fumoleau Pierre; Bonneterre Jacques; Luporsi Elisabeth
Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1190-1; author reply 1191-2.
-
2003: Dittrich C; Coudert B; Paz-Ares L; Caponigro F; Salzberg M; Gamucci T; Paoletti X; Hermans C; Lacombe D; Fumoleau P;
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 2003;39(3):330-4.
-
2003: Kerbrat P; Dieras V; Pavlidis N; Ravaud A; Wanders J; Fumoleau P;
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2003;39(3):317-20.
-
2003: Fumoleau Pierre; Kerbrat Pierre; Romestaing Pascale; Fargeot Pierre; Brémond Alain; Namer Moïse; Schraub Simon; Goudier Marie-Jo; Mihura Jeanne; Monnier Alain; Clavère Pierre; Serin Daniel; Seffert Philippe; Pourny Christiane; Facchini Thomas; Jacquin Jean-Philippe; Sztermer Jean-François; Datchary Jean; Ramos René; Luporsi Elisabeth
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):298-305.
-
2002: van Kesteren Charlotte; Mathôt R A A; Raymond E; Armand J P; Fumoleau P; Punt C; Ravic M; Wanders J; Beijnen J H; Schellens J H M;
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
British journal of clinical pharmacology 2002;54(5):463-71.
-
2002: Bugat Roland; Variol Philippe; Roché Henri; Fumoleau Pierre; Robinet Gilles; Senac Isabelle
The effects of food on the pharmacokinetic profile of oral vinorelbine.
Cancer chemotherapy and pharmacology 2002;50(4):285-90.
-
2002: Van Kesteren Ch; Mathôt R A A; Raymond E; Armand J P; Dittrich Ch; Dumez H; Roché H; Droz J P; Punt C; Ravic M; Wanders J; Beijnen J H; Fumoleau P; Schellens J H M;
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4065-73.
-
2002: Raymond E; ten Bokkel Huinink W W; Taïeb J; Beijnen J H; Faivre S; Wanders J; Ravic M; Fumoleau P; Armand J P; Schellens J H M;
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3508-21.
-
2002: Raymond E; Campone M; Stupp R; Menten J; Chollet P; Lesimple T; Fety-Deporte R; Lacombe D; Paoletti X; Fumoleau P;
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
European journal of cancer (Oxford, England : 1990) 2002;38(10):1348-50.
-
2002: O'Shaughnessy Joyce; Miles David; Vukelja Svetislava; Moiseyenko Vladimir; Ayoub Jean-Pierre; Cervantes Guadalupe; Fumoleau Pierre; Jones Stephen; Lui Wing-Yiu; Mauriac Louis; Twelves Chris; Van Hazel Guy; Verma Shailendra; Leonard Robert
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(12):2812-23.
-
2002: Twelves C; Campone M; Coudert B; Van den Bent M; de Jonge M; Dittrich C; Rampling R; Sorio R; Lacombe D; de Balincourt C; Fumoleau P;
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):777-80.
-
2002: Dittrich Ch; Greim G; Borner M; Weigang-Köhler K; Huisman H; Amelsberg A; Ehret A; Wanders J; Hanauske A; Fumoleau P
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1072-80.
-
2002: Schrijvers D; Bos A M E; Dyck J; de Vries E G E; Wanders J; Roelvink M; Fumoleau P; Bortini S; Vermorken J B
Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):385-91.
-
2002: Campone Mario; Fumoleau Pierre
[Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice]
Bulletin du cancer 2002;89(3):275-82.
-
2002: Borner M M; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters G J; van der Born K; Wanders J; de Boer R F; Martin C; Fumoleau P
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(3):349-58.
-
2002: Caponigro F; Dittrich C; Sorensen J B; Schellens J H M; Duffaud F; Paz Ares L; Lacombe D; de Balincourt C; Fumoleau P
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(1):70-4.
-
2001: Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(11):1643-9.
-
2001: Coudert B; Anthoney A; Fiedler W; Droz J P; Dieras V; Borner M; Smyth J F; Morant R; de Vries M J; Roelvink M; Fumoleau P;
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
European journal of cancer (Oxford, England : 1990) 2001;37(17):2194-8.
-
2001: Punt C J; Fumoleau P; van de Walle B; Faber M N; Ravic M; Campone M
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(9):1289-93.
-
2001: Ravaud A; Borner M; Schellens J H; Geoffrois L; Schöffski B P; Kroon K; Wanders J; Hanauske A R; Fumoleau P;
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1642-7.
-
2001: Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin J P; Bissery M C; Riva A; Azli N
Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(7):909-18.
-
2001: Oudard S; Caty A; Humblet Y; Beauduin M; Suc E; Piccart M; Rolland F; Fumoleau P; Bugat R; Houyau P; Monnier A; Sun X; Montcuquet P; Breza J; Novak J; Gil T; Chopin D
Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(6):847-52.
-
2001: Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero J M; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Oncology 2001;60(4):303-7.
-
2000: Fumoleau P; Déporte R; Kerbrat P; Bonneterre J; Fargeot P
UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):50-5.
-
2000: Roche H; Cure H; Adenis A; Fargeot P; Terret C; Lentz M A; Madelmont J C; Fumoleau P; Hanausk A; Chollet P
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.
Journal of neuro-oncology 2000;49(2):141-5.
-
2000: Rebattu P; Coudert B; Schneider M; Ouabdesselam R; Lentz M; Hanauske A; Chevallierdagger B; Fumoleau P; Chollet P
[Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma]
Revue de pneumologie clinique 2000;56(3):200-3.
-
2000: Pavlidis N; Aamdal S; Awada A; Calvert H; Fumoleau P; Sorio R; Punt C; Verweij J; van Oosterom A; Morant R; Wanders J; Hanauske A R
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Cancer chemotherapy and pharmacology 2000;46(2):167-71.
-
1999: Cure H; Souteyrand P; Ouabdesselam R; Roche H; Ravaud A; D'incan M; Viens P; Fargeot P; Lentz M A; Fumoleau P; Hanauske A; Chollet P
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
Melanoma research 1999;9(6):607-10.
-
1999: Lhommé C; Fumoleau P; Fargeot P; Krakowski Y; Dieras V; Chauvergne J; Vennin P; Rebattu P; Roche H; Misset J L; Lentz M A; Van Glabbeke M; Matthieu-Boué A; Mignard D; Chevallier B
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3136-42.
-
1999: Fumoleau P; Déporte-Fety R; Kerbrat P; Laguerre B
UFT plus oral calcium folinate/vinorelbine for advanced breast cancer.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):86-90.
-
1998: Degardin M; Oliveira J; Geoffrois L; Rolland F; Armand J P; Bastit P; Chauvergne J; Fargeot P; van Glabbeke M; Lentz M A; Tresca P; Boudillet J; Fumoleau P; Cappelaere P
An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1103-7.
-
1998: Curé H; Krakowski I; Adenis A; Tubiana N; Kerbrat P; Roché H; Chevallier B; Lentz M A; Fumoleau P; Chollet P
Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.
European journal of cancer (Oxford, England : 1990) 1998;34(3):422-3.
-
1997: Diéras V; Fumoleau P; Kalla S; Misset J L; Azli N; Pouillart P
Docetaxel in combination with doxorubicin or vinorelbine.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 7():S20-2.
-
1997: Fumoleau P; Féty R; Delecroix V; Perrocheau G; Azli N
Docetaxel combined with vinorelbine: phase I results and new study designs.
Oncology (Williston Park, N.Y.) 1997;11(6 Suppl 6):29-31.
-
1996: Lhommé C; Kerbrat P; Lejeune C; Guastalla J P; Fumoleau P; Goupil A; Héron J F; Cassin M A; Pruvot I; Soares J A; Chazard M
Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.
Seminars in oncology 1996;23(5 Suppl 12):48-54.
-
1996: Dieras V; Fumoleau P; Bourgeois H; Misset J L; Azli N; Pouillart P
Taxoids in combination chemotherapy for metastatic breast cancer.
Anti-cancer drugs 1996;7 Suppl 2():47-52.
-
1996: Fumoleau P
Treatment of patients with liver metastases.
Anti-cancer drugs 1996;7 Suppl 2():21-3.
-
1996: Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset J L; Lentz M A; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
British journal of cancer 1996;74(4):650-6.
-
1996: Misset J L; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1136-45.
-
1996: Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset J L; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(2):165-71.
-
1996: Pujade-Lauraine E; Guastalla J P; Colombo N; Devillier P; François E; Fumoleau P; Monnier A; Nooy M; Mignot L; Bugat R; Marques C; Mousseau M; Netter G; Maloisel F; Larbaoui S; Brandely M
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):343-50.
-
1996: Urosevic V; Chollet P; Adenis A; Chauvergne J; Fargeot P; Roche H; Kerbrat P; Lentz M A; Fumoleau P; Chevallier B
Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):181-2.
-
1995: Fumoleau P; Perrocheau G; Maugard-Louboutin C; Lemevel B
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy]
Bulletin du cancer 1995;82(8):629-36.
-
1995: Chevallier B; Chollet P; Merrouche Y; Roche H; Fumoleau P; Kerbrat P; Genot J Y; Fargeot P; Olivier J P; Fizames C
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1564-71.
-
1995: Fumoleau P; Delozier T; Extra J M; Canobbio L; Delgado F M; Hurteloup P
Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.
Seminars in oncology 1995;22(2 Suppl 5):22-8; discussion 28-9.
-
1995: Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz M A; Van Glabbeke M
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):314-22.
-
1995: Adenis A; Pion J M; Fumoleau P; Pouillart P; Marty M; Giroux B; Bonneterre J
Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer.
Cancer chemotherapy and pharmacology 1995;35(6):527-8.
-
1995: Fumoleau P; Chevallier B; Kerbrat P; Dieras V; Azli N; Bayssas M; Van Glabbeke M
Current status of Taxotere (docetaxel) as a new treatment in breast cancer.
Breast cancer research and treatment 1995;33(1):39-46.
-
1994: Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]
La Clinica terapeutica 1994;145(8):113-21.
-
1994: Guastalla J P; Lhommé C; Dauplat J; Namer M; Bonneterre J; Oberling F; Pouillart P; Fumoleau P; Kerbrat P; Tubiana N
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S33-8.
-
1994: Louboutin J P; Maugard-Louboutin C; Fumoleau P
Leptomeningeal infiltration in esthesioneuroblastoma: report of two cases with poor prognosis.
European neurology 1994;34(4):236-8.
-
1993: Fumoleau P; Delgado F M; Delozier T; Monnier A; Gil Delgado M A; Kerbrat P; Garcia-Giralt E; Keiling R; Namer M; Closon M T
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(7):1245-52.
-
1993: Peltier P; Dutin J P; Chatal J F; Fumoleau P; Bourguet P; Liehn J C; Vuillez J P; Hérry J Y; Loboguerrero A
Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC 125) specific for CA 125 antigen. The INSERM Research Network (Nantes, Rennes, Reims, Vuillejuif, Saclay.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(4):307-11.
-
1993: Pujade-Lauraine E; Guastella J P; Colombo N; François E; Fumoleau P; Monnier A; Nooy M A; Mignot L; Bugat R; Oliviera C M
[Intraperitoneal administration of interferon gamma. An efficient adjuvant to the chemotherapy of ovarian cancers. Apropos of an European study of 108 patients]
Bulletin du cancer 1993;80(2):163-70.
-
1993: Chauvergne J; Fumoleau P; Cappelaere P; Metz R; Armand J P; Chevallier B; Kerbrat P; de Forni M; Lhommé C; Roche H
Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).
European journal of cancer (Oxford, England : 1990) 1993;29A(3):350-4.
-
1993: Kerbrat P; Adenis A; Rebattu P; Roche H; Chevallier B; Chollet P; Krakowski I; Lentz M A; Fumoleau P
Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.
European journal of cancer (Oxford, England : 1990) 1993;29A(11):1597-9.
-
1993: Fumoleau P; Devaux Y; Vo Van M L; Kerbrat P; Fargeot P; Schraub S; Mihura J; Namer M; Mercier M
Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
Drugs 1993;45 Suppl 2():38-45.
-
1992: Guastalla J P; Pujade-Lauraine E; Colombo N; Namer N; Fumoleau P; Monnier A; Nooy M A; Falkson G; Mignot L; Bugat R
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group]
Pathologie-biologie 1992;39(9):831-2.
-
1992: Morais J; Peltier P; Chatal J F; Fumoleau P; Chetanneau A; Bourguet P
Anti-beta HCG abdominopelvic immunoscintigraphy in patients with resistant gestational trophoblastic disease.
Nuclear medicine communications 1992;13(6):464-6.
-
1992: Garcia-Giralt E; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A; Guerin D; Guerin R
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
Breast cancer research and treatment 1992;24(2):139-45.
-
1992: Cappelaere P; Guiochet N; Chauvergne J; Bastit P; Armand J P; Lentz M A; Van Glabbeke M; Herait P; Fumoleau P
Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):484-5.
-
1992: Avril M F; Bonneterre J; Cupissol D; Grob J J; Kalis B; Fumoleau P; Kerbrat P; Israel L; Fargeot P; Lambert D
Fotemustine plus dacarbazine for malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1992;28A(11):1807-11.
-
1991: Vuillez J P; Peltier P; Mayer J C; Dubois F; Chetanneau A; Fumoleau P; Bertrand A; Chatal J F
Reproducibility of image interpretation in immunoscintigraphy performed with indium-111- and iodine-131-labeled OC125 F(ab')2 antibody injected into the same patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1991;32(2):221-7.
-
1990: Chevallier B; Fumoleau P; Kerbrat P; Monnier A; Roche H; Goudie M J; Herait P
Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer.
American journal of clinical oncology 1990;13 Suppl 1():S40-3.
-
1990: Fumoleau P; Bastit P; Horner D; Chauvergne J; Metz R; Bugat R; Cappelaere P
[Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]
Bulletin du cancer 1990;77(8):805-10.
-
1990: Spielmann M; Kerbrat P; Delozier T; Fumoleau P; Monnier A; Chevallier B; Bastit P; Namer M; Cattan A; Lucas P
Pirarubicin in advanced breast cancer: a French cooperative phase II study.
European journal of cancer (Oxford, England : 1990) 1990;26(7):821-3.
-
1989: Chatal J F; Saccavini J C; Gestin J F; Thédrez P; Curtet C; Kremer M; Guerreau D; Nolibé D; Fumoleau P; Guillard Y
Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.
Cancer research 1989;49(11):3087-94.
-
1987: Chatal J F; Fumoleau P; Saccavini J C; Thedrez P; Curtet C; Bianco-Arco A; Chetanneau A; Peltier P; Kremer M; Guillard Y
Immunoscintigraphy of recurrences of gynecologic carcinomas.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1987;28(12):1807-19.
-
1986: Hurteloup P; Armand J P; Cappelaere P; Metz R; Kerbrat P; Keiling R; Fumoleau P; Fargeot P; Schraub S; Bastit P
Phase II clinical evaluation of doxifluridine.
Cancer treatment reports 1986;70(6):731-7.
-
1986: Garcia-Giralt E; Guinet F; Pouillart P; Kerbrat P; Gedouin D; Allain Y M; Fumoleau P
[Phase II trial of pepleomycin in metastatic cancer of the prostate]
Bulletin du cancer 1986;73(1):91-2.
-
1984: Chatal J F; Saccavini J C; Fumoleau P; Douillard J Y; Curtet C; Kremer M; Le Mevel B; Koprowski H
Immunoscintigraphy of colon carcinoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1984;25(3):307-14.
-
1984: Ricolleau G; Chatal J F; Fumoleau P; Kremer M; Douillard J Y; Curtet C
Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1984;5(3-4):151-9.
-
1983: Chatal J F; Bourdoiseau M; Fumoleau P; Douillard J Y; Kremer M; Curtet C; Le Mevel B
[Use of radio-labelled monoclonal antibodies for the scintigraphic detection of human colorectal cancers]
Bulletin du cancer 1983;70(2):103-7.
Sign-in to see more
